Paul-Ehrlich-Institut
Paul-Ehrlich-Institut
06/25/2026 | News release | Distributed by Public on 06/24/2026 23:57
Pharmacovigilance Data on Vaccines (excluding COVID-19 Vaccines) from 2024 and 2025
Pharmacovigilance Data on Vaccines (excluding COVID-19 Vaccines) from 2024 and 2025
Source: Jo Panuwat D/Shutterstock.com
Vaccinations are an effective measure for protecting against infectious diseases and thus for safeguarding the health of all sections of the population. Gaps in vaccination coverage can lead to outbreaks of vaccine-preventable diseases. To strengthen confidence in vaccination, it is important to promptly detect, investigate and transparently communicate both real and perceived risks associated with vaccines. The principle behind this is that suspected cases of adverse drug reactions following vaccination (side effects) should be reported as numerous as possible. The following section presents an overview of suspected cases of adverse drug reactions following vaccination reported to the Paul-Ehrlich-Institut in 2024 and 2025. Suspected cases relating to all vaccines authorised and marketed in Germany, with the exception of COVID-19 vaccines, were evaluated. The analysis of pharmacovigilance data for these vaccines for the year 2025 will be conducted separately.
Updated: 25.06.2026
Paul-Ehrlich-Institut published this content on June 25, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 25, 2026 at 05:57 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]